Reimbursement issues can be challenging for an injectable product. Roche has provided this site as a reimbursement resource for health care providers and their staff for BONIVA Injection.
Important Safety Information for BONIVA Injection
BONIVA Injection is contraindicated in patients with uncorrected hypocalcemia or known hypersensitivity to BONIVA Injection or any of its excipients. BONIVA Injection, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values. Hypocalcemia, hypovitaminosis D, and other disturbances of bone and mineral metabolism must be effectively treated before starting therapy. Patients must receive supplemental calcium and vitamin D. BONIVA Injection must only be administered intravenously by a healthcare professional. Patients who receive BONIVA Injection should have serum creatinine measured prior to each dose. BONIVA Injection should not be administered to patients with severe renal impairment (creatinine clearance <30 mL/min). Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures who received intravenous bisphosphonates.
In a one-year study comparing BONIVA Injection 3 mg quarterly and BONIVA Tablets 2.5 mg daily, the overall safety and tolerability profiles with the two dosing regimens were similar. The most commonly reported adverse events (¡Ý5%) regardless of causality were arthralgia (9.6% BONIVA Injection vs 8.6% BONIVA Tablet 2.5 mg), back pain (7.0% vs 7.5%), hypertension (5.3% vs 7.1%), abdominal pain (5.1% vs 5.6%), influenza (4.7% vs 8.0%) and nasopharyngitis (3.4% vs 6.0%). In some patients acute phase reaction-like events (10% BONIVA Injection vs 4% BONIVA Tablet) have been reported within 3 days of an IV dose and lasting for 7 days or less, most commonly after the first injection. In most cases, no specific treatment was required and symptoms subsided in 24-48 hours.
Disclaimer
While every effort is made to provide helpful information, Roche makes no representations about the eligibility or guarantee of coverage or reimbursement for any particular claim. Roche cannot guarantee success in obtaining third-party insurance reimbursement. Third-party payment for medical products and services is affected by numerous factors. It is always a provider's responsibility to determine and submit the appropriate codes, charges, and modifiers for services that are rendered. Providers should contact third-party payors for specific information on their coding, coverage and payment policies.
Copyright © 2007 - 2009
Hoffmann-La Roche Inc.
All Rights Reserved.
The information provided on this site is for informational purposes only and does not take the place of talking to your healthcare provider about your medical condition or treatment.
Privacy Policy | Legal Statement | Contact Us
BONIVA and symbol are trademarks of Roche Therapeutics, Inc.
